New FcGR2B cell line: Boost your Immunotherapeutic antibody development

Monoclonal antibodies (mAbs) are used as immunotherapeutics to treat cancer and other diseases, and either aim to induce target cell destruction or immune cell activation. After binding to their cognate antigens, mAbs engage Fc gamma receptor  (FcγR), localised on the surface of the Immune cells, and identified by many research groups as regulator of mAbs activity. To help researchers working on immunotherapeutic mAbs development, BPS Bioscience have developed a new CHO K1 cell line stably expressing full length human FcGR2B.

In the family of the receptors for Immunoglobulins G (FcγRs), FcGR2B (also known as CD32B) which is highly expressed in B cells, is the only inhibitory receptor in mice and humans, and binds to monomeric IgG with a low affinity.

Usually studied by researchers as a target for B-cell related diseases such as leukemia, anti-FcGR2B antibodies have shown anti-tumour activity, but this protein also has a great interest as a regulator of the immune system and the final activity of immunotherapeutic antibodies.  Numerous studies have shown that high expression of FcGR2B negatively regulates mAb-mediated immunotherapy, so blocking FcGR2B activity can improve the response to immunotherapeutic mAbs.  For example, FcGR2B-blocking antibodies prevent internalization of the CD20-specific mAb rituximab, which maximizes cell surface accessibility and anti-tumour activity of the rituximab (1). But interestingly, it has been shown (2) that the engagement of the inhibitory CD32B, more than being only detrimental, can also be beneficial to therapeutic efficacy depending on the type of mAb and context.

Fig. 1: Dose Response of anti-CD137 antibody on CD137/ NF-κB Reporter HEK293 cells co-cultured with FcGR2B CHO K1 cells.

In this optic, BPS Bioscience have developed a new FcGR2B cell line. Using this cell line, they have demonstrated the significant improvement of anti-CD137 (fig. 1) and anti-OX40 agonist Ab activities, by Ab cross-linking.

By allowing you to…

  1. Screen for activators or inhibitors of antibody mediated signaling by co-culturing with the FcGR2B CHO K1 cells
  2. Characterize the agonist activity of antibodies by crosslinking to the FcGR2B receptor

…this new FcGR2B cell line will help you in the development of new immunotherapeutic mAbs against CD137, OX40 or other immune checkpoints and immunotherapy targets.

Interested in this FcGR2B Cell Line?

Contact your tebu-bio local office and benefit from the new lower prices and take advantage of the Risk free Cell Line rental program – you can try the cell line during 3 months for only half of the price.

And there’s more…

Here are some other products that will also be of interest to you for your research:

Finally, take a moment to browse these other cell lines for Drug Discovery and Immunotherapy Checkpoint research.

References:

(1): Roghanian A. et al, Cancer Cell. 2015 Apr 13;27(4):473-88. 

(2): Stopforth RJ. et al, J Clin Immunol. 2016 May;36 Suppl 1:88-94.

Frédéric Samazan
Written by Frédéric Samazan
Frédéric Samazan is a Product Manager at tebu-bio, and an avid football fan in his spare time.